Literature DB >> 31783062

Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease.

Page E Crew1, Lucy McNamara2, Peter E Waldron3, Lynda McCulley3, S Christopher Jones3, Susan J Bersoff-Matcha4.   

Abstract

Entities:  

Keywords:  Antibiotic prophylaxis; Eculizumab; Neisseria meningitidis

Year:  2019        PMID： 31783062      PMCID： PMC7197327          DOI： 10.1016/j.jinf.2019.11.015

Source DB:  PubMed          Journal:  J Infect        ISSN： 0163-4453            Impact factor:   6.072


× No keyword cloud information.
  7 in total

1.  Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents.

Authors:  James H Jorgensen; Sharon A Crawford; Kristin R Fiebelkorn
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

2.  Unusual Neisseria species as a cause of infection in patients taking eculizumab.

Authors:  Page E Crew; Lucy McNamara; Peter E Waldron; Lynda McCulley; S Christopher Jones; Susan J Bersoff-Matcha
Journal:  J Infect       Date:  2018-11-06       Impact factor: 6.072

3.  Determination of CEM-101 activity tested against clinical isolates of Neisseria meningitidis from a worldwide collection.

Authors:  Douglas J Biedenbach; Mariana Castanheira; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

4.  Disseminated Gonococcal Infections in Patients Receiving Eculizumab: A Case Series.

Authors:  Page E Crew; Winston E Abara; Lynda McCulley; Peter E Waldron; Robert D Kirkcaldy; Emily J Weston; Kyle T Bernstein; S Christopher Jones; Susan J Bersoff-Matcha
Journal:  Clin Infect Dis       Date:  2019-08-01       Impact factor: 9.079

5.  Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab.

Authors:  Sydel R Parikh; Jay Lucidarme; Coralie Bingham; Paul Warwicker; Tim Goodship; Ray Borrow; Shamez N Ladhani
Journal:  Pediatrics       Date:  2017-08-11       Impact factor: 7.124

6.  High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine.

Authors:  Lucy A McNamara; Nadav Topaz; Xin Wang; Susan Hariri; LeAnne Fox; Jessica R MacNeil
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-07-14       Impact factor: 17.586

7.  Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab.

Authors:  Deirdre Nolfi-Donegan; Monica Konar; Vianca Vianzon; Jessica MacNeil; James Cooper; Perrianne Lurie; Judi Sedivy; Xin Wang; Dan M Granoff; Lucy McNamara
Journal:  Emerg Infect Dis       Date:  2018-08       Impact factor: 6.883
  7 in total
  3 in total

1.  The Benefits of Complement Measurements for the Clinical Practice.

Authors:  Anne Grunenwald; Lubka T Roumenina
Journal:  Methods Mol Biol       Date:  2021

2.  Acquisition of Ciprofloxacin Resistance Among an Expanding Clade of β-Lactamase-Positive, Serogroup Y Neisseria meningitidis in the United States.

Authors:  Caelin C Potts; Adam C Retchless; Lucy A McNamara; Daya Marasini; Natashia Reese; Stephanie Swint; Fang Hu; Shalabh Sharma; Amy E Blain; David Lonsway; Maria Karlsson; Susan Hariri; LeAnne M Fox; Xin Wang
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 20.999

3.  Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.

Authors:  Sasha A Živković; Gregory Gruener; Pushpa Narayanaswami
Journal:  Muscle Nerve       Date:  2021-01-27       Impact factor: 3.217
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.